DelveInsight’s, “Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists Pipeline Insights 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists pipeline landscape. It covers the Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Pipeline Report
- DelveInsight’s Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist treatment.
- The leading companies working in the Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Market include Amgen, University of Maryland, Baltimore, Nvision Laser Eye Centers, and others.
- Promising Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Pipeline Therapies in the various stages of development include Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe, Injection for SC administration (120mg/syringe), and others.
- January 2023: University of Maryland, Baltimore announced a study of Phase 2 clinical trials for Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe. The study will be a randomized, double blind, placebo-controlled trial comparing erenumab-aooe vs Placebo. The study drug is erenumab-aooe 70mg, SC injection. Participants will attend 6 clinic visits (Visit 0-Visit 5) over a period of 21 weeks (20 +/- 1 weeks) or 140 +/- 7 days. After randomization and on Visit 1 (Week 4/Day 28), the participant will receive the drug or placebo. This same treatment will be administered once a month for 3 months (3 cycles/12 weeks). It will be administered on Visit 1/Day 28/Week 4; Visit 2/Day 56/Week 8; and Visit 3/Day 84/week 12. On Visit 0 (baseline) and on Visit 1, Visit 2, Visit 3, Visit 4/Day 112/Week 16 and visit 5/Day 140/Week 20, visits will include review of compliance with inclusion criteria, medical history review, review and collection of any adverse event, clinical examinations, questionnaires, tests, blood sample collection on Baseline/Visit 0 and Visit 4; and instruction to complete the DSD and questionnaires.
Request a sample and discover the recent advances in Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Treatment Drugs @ Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Pipeline Report
In the Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Overview
CGRP is a 37-amino acid peptide identified for the first time in 1982, which functions as a potent vasodilator of almost all vascular beds. Specifically, the cranial, mesenteric and coronary arteries have been shown to be densely innervated with CGRP-positive fibers. The relaxant effect of CGRP on smooth muscle cells seems to be more prominent in the distal as compared to the proximal coronary arteries. Most importantly, CGRP is involved in nociceptive transmission in the trigeminal ganglion, the trigeminocervical complex and trigeminothalamic pathway.
Find out more about Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Therapeutics Assessment @ Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Preclinical and Discovery Stage Products
Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Emerging Drugs Profile
- Zavegepant (BHV-3500): Biohaven Pharmaceutical
- Aimovig (erenumab): Amgen Inc.
- Galcanezumab: Eli Lilly and Company
Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists. The companies which have their Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists drug candidates in the most advanced stage, i.e. phase III include, Biohaven Pharmaceuticals, Inc., Novartis etc.
DelveInsight’s Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Pipeline Report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase II and Phase II/III)
- Mid-stage products (Phase II and Phase II/III)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intravenous
- Oral
- Molecule Type
Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Pipeline Products have been categorized under various Molecule types such as
- Monoclonal antibodies
- Small molecules
- Product Type
Learn more about the emerging Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Pipeline Therapies @ Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Clinical Trials Assessment
Scope of the Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Pipeline Report
- Coverage- Global
- Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Companies- Amgen, University of Maryland, Baltimore, Nvision Laser Eye Centers, and others.
- Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Pipeline Therapies- Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe, Injection for SC administration (120mg/syringe), and others.
Dive deep into rich insights for new drugs for Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Treatment, Visit @ Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists Collaboration Deals
- Late Stage Products (Phase III)
- Zavegepant: Biohaven Pharmaceuticals, Inc.
- Mid Stage Products (Phase II)
- Erenumab: Amgen / Novartis
- Inactive Products
- Comparative Analysis
- Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists- Market Drivers and Barriers
For further information on the Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Pipeline therapeutics, reach out to Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services